


New drug candidate developed to treat type 2 diabetes

August 26 2022, by Birgit Niesing



GLP-1RA/tesaglitazar in obese GLP-1R knockout mice. a–n, Body weight (a,h), change in fat and lean tissue mass (b,c,i,j), cumulative food intake (d,k), blood glucose (e,l) and i.p. GTT (f,m) in 36-week-old male DIO wildtype (WT) (a–g) or GLP-1R knockout (KO) mice (h–n) treated for 6 days with either vehicle or 50 nmol kg⁻¹ per day of GLP-1RA/tesaglitazar. Sample sizes for treatment with Vhcl or GLP-1RA/tesaglitazar are n = 8/8 (a–c,e,f), n = 8/7 (g) and n = 7/7 (h–j,l–n). Cumulative food intake was assessed per cage in n = 4/3 cages containing n = 8/8 mice (d) and n = 4/5 cages containing n = 7/7 mice (k). Data in a, d, f, h, k and m have been analyzed by two-way ANOVA with Bonferroni post hoc comparison for individual time points. Data in b, c, e, g, i, j, l and n have been analyzed by one-way ANOVA using Bonferroni's multiple comparison test. Data represent means ± s.e.m.; asterisks indicate *P

Citation: New drug candidate developed to treat type 2 diabetes (2022, August 26) retrieved 3

May 2024 from <https://medicalxpress.com/news/2022-08-drug-candidate-diabetes.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.